A simpler diabetes tech is in the offing, but some patients are yet to be convinced that a device knows best.
The nightmare on the public markets is not confined to the bigger groups.
New devices are coming, but the real advances will involve combinations.
The diabetes-focused Becton Dickinson spinoff intends to spend – but can it compete in insulin pumps?
Insulin pumps and glucose sensors flew off the shelves, whereas liquid biopsy developers both soared and sank.
Pivotal data on its closed-loop insulin delivery system look good, but Medtronic remains a threat.